Premium
PUVA treatment and choroidal malignant melanoma
Author(s) -
Haciyakupoǧlu Gülhanim,
Varinli Ilter,
Memisoĝlu Hamdi R.,
Varinli Seyhan,
Demircan Nihal,
Denli Gul
Publication year - 1993
Publication title -
acta ophthalmologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.534
H-Index - 87
eISSN - 1755-3768
pISSN - 1755-375X
DOI - 10.1111/j.1755-3768.1993.tb08613.x
Subject(s) - medicine , dermatology , puva therapy , enucleation , psoralen , melanoma , psoriasis , vitiligo , ocular melanoma , incidence (geometry) , surgery , cancer research , dna , genetics , physics , optics , biology
. Choroidal malign melanoma showing rapid progression in a boy 17 years old is presented. The patient was under therapy with methoxy psoralen + Ultraviolet A (PUVA)* for psoriasis vulgaris. He had undergone complete ophthalmologic examinations with three‐month intervals from the beginning of this therapy. The tumor was detected in the seventh month, rapidly enlarging within the next twenty days, and eventually leading to enucleation. PUVA is known to be a risk factor for cutaneous malign melanoma. However, there is no reported incidence of choroidal malign melanoma in PUVA treated patients. To our knowledge, this is the only case showing the possible role of PUVA therapy as a predisposing factor in the development of uveal malign melanoma.